Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Effects of Expanded Hemodialysis with Medium Cut-Off Membranes on Maintenance Hemodialysis Patients: A Review
Visit resource site
PD
Effects of Glucose-Free Dialysis Solutions on Human Peritoneal Mesothelial Cells - Chang JM, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of Hemodialysis Therapy Using Dialyzers with Medium Cut-Off Membranes on Middle Molecules - Kirsch AH, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of medium cut-off (Theranova) dialyzer on hemodialysis patients: a prospective, crossover study - Cozzolino M et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of medium cut-off dialysis membranes on inflammation and oxidative stress in patients on maintenance hemodialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of Medium Cut-Off Polyarylethersulfone and Polyvinylpyrrolidone Blend Membrane Dialyzers in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of Medium Cut-Off Versus High-Flux Hemodialysis Membranes on Biomarkers: A Systematic Review and Meta-Analysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of Medium Cutoff Membranes on Pro-Inflammatory Cytokine and Oxidative Marker Levels in Patients with Sepsis Who Developed Acute Kidney Injury
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects on clinical and dialytic parameters with a new medium cut off membrane dialyzer in conventional hemodialysis compared to a high flux dialyzer in online hemodiafiltration
Visit resource site
PD
Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis - Plum J, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Efficacy and safety of expanded hemodialysis in hemodialysis patients: a meta-analysis and systematic review
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.